Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus

Krzysztof Domagalski, Małgorzata Pawłowska, Agnieszka Zaleśna, Małgorzata Pilarczyk, Paweł Rajewski, Waldemar Halota, Andrzej Tretyn

AIM
To investigate the impact of IL28B and OAS gene polymorphisms on interferon treatment responses in children with chronic hepatitis B.

METHODS
We enrolled 52 children (between the ages of 4 and 18) with hepatitis B e antigen-negative chronic hepatitis B (CHB), who were treated with pegylated interferon alfa for 48 wk. Single nucleotide polymorphisms in the OAS1 (rs1131476), OAS2 (rs1293747),
OAS3 (rs2072136), OASL (rs10849829) and IL28B (rs12979860, rs12980275 and rs8099917) genes were studied to examine their associations with responses to IFN treatment in paediatric patients. We adopted two criteria for the therapeutic response, achieving an hepatitis B virus (HBV) DNA level <2000 IU/mL and normalization of ALT activity (<40 IU/L). To perform the analyses, we compared the patients in terms of achieving a partial response (PR) and a complete response (CR) upon measurement at the 24-wk post-treatment follow-up.

**RESULTS**

The PR and CR rates were 80.8% and 42.3%, respectively. Factors such as age, gender and liver histology had no impact on the type of response (partial or complete). A statistically significant relationship between higher baseline HBV DNA and ALT activity levels and lower rates of PR and CR was shown ($P < 0.05$). The allele association analysis revealed that only the IL-28B rs12979860 (C vs T) and IL28B rs12980275 (A vs G) markers significantly affected the achievement of PR ($P = 0.021$, OR = 3.3, 95%CI: 1.2-9.2 and $P = 0.014$, OR = 3.7, 95%CI: 1.3-10.1, respectively). However, in the genotype analysis, only IL-28B rs12980275 was significantly associated with PR (AA vs AG-GG, $P = 0.014$, OR = 10.9, 95%CI: 1.3-93.9). The association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group ($P = 0.033$) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group ($P = 0.044$, OR = 0.26, 95%CI: 0.07-0.88). The haplotype analysis revealed significant associations between PR and CR and OAS haplotype ($P = 0.0002$ and $P = 0.001$, respectively), but no association with IL28B haplotype was observed.

**CONCLUSION**

IL28B and OAS polymorphisms are associated with different clinical outcomes in CHB children treated with interferon.

**Key words:** Chronic hepatitis B; IL28B; OAS; Single-nucleotide polymorphisms; IFN therapy; Children

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The limited efficacy and side effects associated with IFN treatment limit its clinical use in paediatric patients with chronic hepatitis B (CHB). Therefore, pretreatment predictors are required to identify those patients at highest risk for treatment response failure. OAS and IL28B are well-known IFN-induced antiviral pathway players; however, the impact of host-related genetic variability in the IL28B and OAS genes on response rates to IFN therapy in CHB paediatric patients has not been studied. The results of our study show an association between IL28B rs12979860, OASL rs10849829 and OAS haplotypes and final IFN-treatment response in Caucasian CHB children.

**INTRODUCTION**

It is estimated that at least 2 billion people worldwide have serologic evidence of contact with HBV, including approximately 350 million people who develop chronic hepatitis B (CHB)\(^{[1-2]}\). The largest proportion of chronic cases occurs in children infected in the first years of life; this figure reaches 90% in the case of infection in the perinatal period\(^{[1,3,4]}\). Despite the significant decrease in the number of new cases of CHB in children because of the introduction of compulsory vaccination in many countries, we are still struggling with the treatment of adolescent patients, especially in developing countries\(^{[5-7]}\).

A 48-wk course of interferon therapy is recommended as a first-line treatment option for select HBeAg-negative patients, especially young patients with increased aminotransferase activity, which indicates the activation of the immune system to eliminate infected hepatocytes, and providing a therapy with antiviral and immunomodulatory activity in the form of interferon may enhance this effect\(^{[8,9]}\). However, PEG-IFN-based therapy is modestly effective in suppressing viral replication in comparison to nucleos(t)ide analogues, which are highly effective in suppressing HBV replication. In contrast to nucleos(t)ide analogues, PEG-IFN-based therapy has a higher HBsAg seroconversion rate\(^{[10-12]}\). Therefore, pretreating patients to identify those with the highest probability of success is of great clinical importance to IFN therapy.

The antiviral activity of interferons is associated with their ability to induce virus targeting proteins such as 2'-5'-oligoadenylate synthetase (2',5'-OAS)\(^{[13]}\). Analytic studies in human hepatocytes have confirmed that both interferon alfa and interferon lambda, which includes interleukin 28B, have activating effects\(^{[14]}\). The OAS proteins are well-known IFN-induced antiviral pathway players involved in the cleavage of viral RNA molecules, resulting in the inhibition of viral replication. The human OAS family contains the OAS1, OAS2, OAS3, and OASL genes, which are located on chromosome 12 (in the 12q24.1 region)\(^{[15,16]}\). Single-nucleotide polymorphisms (SNPs) in the OAS family genes have been identified as a factor associated with...
susceptibility to viral infection and antiviral effects during IFN-based therapy in patients infected with HCV[17-20].

The influence of host-related genetic variability on differences in response rates to IFN therapy in CHB patients is not well understood. Unlike many studies confirming that SNPs in the interleukin 28B (IL28B) gene play a primary role in IFN-based treatment outcomes in patients with chronic hepatitis C, the association between IL28B SNPs and the result of IFN monotherapy in CHB has been a subject of very few studies[21-23]. Additionally, there is limited information about the role of SNPs in 2',5'-oligoadenylate synthetase (OAS) family genes in the IFN response in hepatitis B patients[24,25]. Currently, there are no available results concerning the impact of IL28B or OAS SNPs on the results of IFN therapy in a group of paediatric patients with CHB.

The aim of this study was to determine the relationship between IL28B and OAS gene family SNPs and the biochemical and virological response rates to PEG-IFN α-2a monotherapy in a cohort of Caucasian children chronically infected with HBV.

**MATERIALS AND METHODS**

**Patients**

We retrospectively enrolled a cohort of CHB children of Caucasian ethnicity who were treated with PEG-IFN α-2a (Pegasys) at a dose of 180 μg per week for 48 wk at the Department of Paediatric Infectious Diseases and Hepatology.

The inclusion criteria were as follows: HBsAg positive for more than 6 mo, confirmed detection of HBV DNA > 2000 IU/mL or abnormal liver biochemistry (alanine aminotransferase (ALT) > 40 IU/L) for a period of one year prior to the start of therapy. All the included patients were treatment naïve, HBeAg-negative, and had completed a 48-wk course of PEG-IFN α-2a monotherapy with a minimum of 24 wk post-therapy follow-up.

The exclusion criteria included hepatitis C virus (HCV) coinfection, human immunodeficiency virus (HIV) coinfection, a coexisting autoimmune disease, cirrhosis, hepatocellular carcinoma (HCC) or chronic liver disease other than CHB. There were no pregnant women in the study group. Blood samples from these patients were used for IL28B and OAS genotyping. Detailed demographic characteristics and other standard clinical data, including the ALT level, HBsAg, HBeAg, and anti-HBe status, HBV DNA level, and liver histology, were obtained from the patients’ clinical documentation. Pre-treatment liver histological analysis was carried out by only one pathologist using the modified Scheuer scoring system (F0–F4; A0–A4).

The study was reviewed and approved by the NCU Bioethics Committee at Collegium Medicum NCU. All procedures conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The patients’ legal guardians and all patients older than 16 signed a written informed consent.

**IL28B and OAS genotyping**

Host genomic DNA was prepared using the QIAamp DNA Mini Kit (Qiagen) from peripheral whole-blood samples collected in 0.5 M EDTA tubes. The detection of IL28B (rs12979780 CT, rs12980275 AG and rs8099917 TG), OASL (rs10849829), OAS1 (rs1131476), OAS2 (rs1293747), and OAS3 (rs2072136) SNPs was carried out with a real-time polymerase chain reaction (real-time PCR) using the TaqMan SNP Genotyping Assays (Applied Biosystems by Life Technologies). For all SNPs, genotyping was performed on a LightCycler® 480 Instrument (Roche Diagnostics) with the following standard reaction conditions: 95 °C for 10 min, 92 °C for 15 s, followed by 35 cycles of 60 °C for 1 min. A population analysis for each genetic marker was performed for all patients.

**Treatment responses**

The main focus of this study was to determine the predictive value of IL28B and OAS SNPs in treatment outcomes. The impact of other prognostic factors on the results of therapy was also analysed. To evaluate the therapeutic effects, we assessed virological, serological and biochemical responses by analysing HBV DNA levels, HBsAg status and ALT activity before, during and 24 wk after the end of therapy. A limit of 2000 IU HBV DNA/mL, which has been used in the literature, was adopted in the virological response analysis[26]. In our study, we determined the impact of genetic markers on the efficacy of therapy by comparing patients in terms of achieving a defined therapeutic response. We adopted two criteria for the therapeutic response, achieving an HBV DNA level < 2000 IU/mL and normalization of ALT activity (< 40 IU/L). To perform the analyses, we compared the patients in terms of achieving a partial response (PR) and a complete response (CR). CR was defined as the suppression of viral replication to an HBV DNA level < 2000 IU/mL and normalization of ALT activity (< 40 IU/L) 24 wk after completing the treatment. To be classified as PR, patients were required to achieve a positive result for at least one of the two parameters. Based on the PR criterion, patients were divided into those who achieved at least one of the two considered parameters and those who did not achieve any positive response 24 wk after completing the treatment. HBV DNA level was assessed with a quantitative polymerase chain reaction assay (cobas AmpliPrep/cobas TaqMan HBV Test; Roche Diagnostics).

**Statistical analysis**

The summary statistics for the continuous variables are presented as the median and range. The categorical variables are presented as frequencies.
of haplotype with treatment response were performed using SHEsis online software[27]. The results were considered statistically significant when the P value was less than 0.05. Odds ratios (OR) and 95%CI were also calculated for the statistically significant results of compared binary clinical variables. The statistical analysis and graphing were completed with the use of IBM SPSS 20 and GraphPad Prism 6 software. The statistical methods of this study were reviewed by a biomedical statistician.

**RESULTS**

**Patient characteristics and treatment responses**

This study recruited 52 Caucasian children chronically infected with HBV, including girls (30.8%) and boys (69.2%), with a median age of 16 years. The clinical characteristics of all the patients treated for CHB are presented in Table 1. All the patients in the present study had a baseline HBV DNA level above 2000 IU/mL; 31 of them had values under 20000 IU/mL (59.6%) at baseline. The median baseline HBV DNA of the entire group was 4.6 log10 IU/mL. Fourteen (26.9%) patients had normal ALT activity (< 40 U/L) at baseline. The median ALT activity was 42 U/L. The pretreatment liver biopsy sample data, which was assessed in all patients, showed that most of the patients had stage F1 (59.6%) and F2 (30.7%) fibrosis and grade A1 (42.3%) and A2 (53.8%) inflammation, according to the modified Scheuer score. None of these patients had cirrhosis. The genotype distributions for the IL28B and OAS family genes are presented in Table 1.

The HBV DNA level < 2000 IU/mL and ALT normalization response rates were 75.0% and 53.9%, respectively, at the end of therapy and 51.9% and 71.2%, respectively, 24 wk post-treatment. The partial and complete response rates were 80.8% and 42.3%, respectively. Two (3.8%) of the analysed patients group achieved HBsAg seroclearance (data not shown).

**Factors associated with PR**

At first, we evaluated the association between clinical baseline characteristics, including the analysed polymorphisms, and PR (Table 2). In general, the univariate analysis showed no relationship between age at start of therapy, gender, liver histology and partial response. In contrast, the baseline HBV DNA level and ALT activity significantly affect the PR. Higher baseline HBV DNA levels and ALT activity were associated with decreased rates of PR.

Analysis of the IL28B and OAS gene family SNPs showed that only the IL28B rs12980275 marker was significantly different in the PR group (AA vs AG-GG, P = 0.014, OR = 10.9, 95%CI: 1.3-93.9). The other two markers had borderline significance (0.068 and 0.075 for CC vs CT- TT of rs12979860 and
Table 2  Impact of clinical and genetic factors on partial response in HBeAg-negative chronic hepatitis B children

| Characteristic       | PR, n = 42 | No-PR, n = 10 | P value | OR (95%CI) |
|----------------------|------------|---------------|---------|------------|
| Age (yr)             |            |               |         |            |
| Median (range)       | 16 (4-18)  | 16 (5-18)     | 0.803   |            |
| Gender               |            |               |         |            |
| Female               | 14 (33.3)  | 2 (20.0)      | 0.412   |            |
| Staging (F)          |            |               |         |            |
| F0-F1                | 26 (61.9)  | 7 (70.0)      | 0.729   |            |
| Grading (A)          |            |               |         |            |
| A0-A1                | 20 (47.6)  | 5 (50.0)      | 0.892   |            |
| Baseline HBV DNA (IU/mL) |        |               |         |            |
| Median (range), log < 2000 | 4.1 (3.4-8.0) | 5.9 (3.6-8.0) | 0.017 |            |
| Baseline ALT (U/L)   |            |               |         |            |
| Median (range) < 40  | 44 (10-120)| 63 (22-118)   | 0.003   |            |
| IL28B rs12979860     |            |               |         |            |
| CC                   | 19 (45.2)  | 1 (10.0)      | 0.068   |            |
| CT                   | 20 (47.6)  | 6 (60.0)      |        |            |
| TT                   | 3 (7.2)    | 3 (30.0)      | 0.077   |            |
| IL28B rs12980275     |            |               |         |            |
| AA                   | 23 (54.8)  | 1 (10.0)      | 0.014   | 10.9 (1.3-93.9) |
| AG                   | 17 (40.6)  | 7 (70.0)      |         |            |
| GG                   | 2 (4.8)    | 2 (20.0)      | 0.163   |            |
| IL28B rs8099917      |            |               |         |            |
| AA                   | 16 (38.1)  | 5 (50.0)      | 0.500   |            |
| AG                   | 20 (47.6)  | 5 (50.0)      |         |            |
| GG                   | 6 (14.3)   | 0 (0.0)       | 0.582   |            |
| OAS1 rs1131476       |            |               |         |            |
| AA                   | 19 (45.2)  | 7 (70.0)      | 0.291   |            |
| AG                   | 15 (35.7)  | 2 (20.0)      |         |            |
| GG                   | 8 (19.1)   | 1 (10.0)      | 0.670   |            |
| OAS2 rs1293747       |            |               |         |            |
| GG                   | 25 (59.5)  | 7 (70.0)      | 0.481   |            |
| GA                   | 15 (35.7)  | 2 (20.0)      |         |            |
| AA                   | 2 (4.8)    | 1 (10.0)      | 0.722   |            |
| OAS3 rs2072136       |            |               |         |            |
| GG                   | 23 (54.8)  | 7 (70.0)      | 1.000   |            |
| GA                   | 17 (40.6)  | 3 (30.0)      |         |            |
| AA                   | 2 (4.8)    | 0 (0.0)       | 0.488   |            |

Data are presented as the number of patients (%) unless otherwise indicated.

TT vs TG-GG of rs8099917, respectively). However, the distributions of allele frequencies for IL28B rs12979860 (C vs T) were significantly different between the PR and no-PR groups (P = 0.021, OR = 3.3, 95%CI: 1.2-9.2), in contrast to rs8099917 (T vs G, P = 0.082) (data not shown). The factors that were significantly associated with PR in the univariate analysis were analysed by logistic regression analysis. We found significant associations for baseline HBV DNA level (P = 0.037, OR = 2.2, 95%CI: 1.1-4.7) and IL28B rs12980275 AA (P = 0.020, OR = 18.8, 95%CI: 1.6-123.2), but not for ALT activity (P = 0.70).

Factors associated with complete response

In the next step, we analysed the significance of the association between baseline factors and complete response (Table 3). The presented data revealed that overall there were no statistically significant differences in the baseline characteristics of the complete response (CR) and no-CR groups in the analysed group of children. However, ALT activity was higher in patients in the no-CR group (48 U/L) compared with patients with the CR group (43 U/L). Additionally, the percentage patients with ALT < 40 U/L was higher in the patients with a CR (36.3% vs 20.0%).

Analyses of the examined polymorphisms showed that only the IL28B rs12979860 and OAS1 rs10849829

Table 3  Impact of clinical and genetic factors on partial response in HBeAg-negative chronic hepatitis B children

| Characteristic       | CR, n = 22 | No-CR, n = 30 | P value | OR (95%CI) |
|----------------------|------------|---------------|---------|------------|
| Age (yr)             |            |               |         |            |
| Median (range)       | 16 (12-18) | 17 (4-18)     | 0.141   |            |
| Gender               |            |               |         |            |
| Female               | 8 (36.4)   | 8 (26.7)      | 0.454   |            |
| Staging (F)          |            |               |         |            |
| F0-F1                | 14 (63.6)  | 19 (63.3)     | 0.942   |            |
| Grading (A)          |            |               |         |            |
| A0-A1                | 10 (45.5)  | 15 (50.0)     | 0.746   |            |
| Baseline HBV DNA (IU/mL) |        |               |         |            |
| Median (range), log < 2000 | 4.6 (3.4-8.0) | 4.7 (3.5-8.0) | 0.671 |            |
| Baseline ALT (U/L)   |            |               |         |            |
| Median (range) < 40  | 43 (10-110)| 48 (17-126)   | 0.116   |            |
| IL28B rs12979860     |            |               |         |            |
| CC                   | 8 (36.4)   | 12 (40.0)     | 0.790   |            |
| CT                   | 14 (63.6)  | 12 (40.0)     |         |            |
| TT                   | 0 (0.0)    | 6 (20.0)      | 0.033   | NA         |
| IL28B rs12980275     |            |               |         |            |
| AA                   | 11 (50.0)  | 13 (43.3)     | 0.634   |            |
| AG                   | 11 (50.0)  | 13 (43.3)     |         |            |
| GG                   | 0 (0.0)    | 4 (13.4)      | 0.128   |            |
| OAS1 rs10849829      |            |               |         |            |
| AA                   | 5 (22.7)   | 16 (53.3)     | 0.026   | 0.26 (0.07-0.88) |
| AG                   | 14 (63.6)  | 11 (36.7)     |         | 0.685     |
| GG                   | 3 (13.6)   | 3 (10.0)      |         |            |
| OAS1 rs1131476       |            |               |         |            |
| AA                   | 10 (45.5)  | 16 (53.3)     | 0.575   |            |
| AG                   | 8 (36.4)   | 9 (30.0)      |         | 0.557     |
| GG                   | 4 (18.1)   | 5 (16.7)      | 0.887   |            |
| OAS2 rs1293747       |            |               |         |            |
| GG                   | 14 (63.6)  | 18 (60.0)     | 0.253   |            |
| GA                   | 8 (36.4)   | 9 (30.0)      |         |            |
| AA                   | 0 (0.0)    | 3 (10.0)      | 0.790   |            |
| OAS3 rs2072136       |            |               |         |            |
| GG                   | 15 (68.2)  | 15 (50.0)     | 1.000   |            |
| GA                   | 6 (27.3)   | 14 (46.7)     |         |            |
| AA                   | 1 (4.5)    | 1 (3.3)       | 0.190   |            |

Data are presented as the number of patients (%) unless otherwise indicated. NA: Not applicable.
markers had an impact on CR results. The recessive genotype distributions for the IL28B rs12979860 polymorphism (CC-CT vs TT) were significantly different between the CR and no-CR groups ($P = 0.033$). These results were observed because none of the 6 children with the rs12979860 TT genotype achieved CR and the proportion of patients with CC-CT genotypes was comparable between the CR and no-CR groups. Despite the lack of statistical significance such as that observed in rs12979860 for the other two IL28B polymorphisms, none of the patients carrying homozygous genotypes for the minor alleles (GG for rs8099917 and GG for rs12980275) achieved CR. In contrast to the PR results, there were no statistically marginal or significant differences in CR rates for the dominant genotype and allele frequency distributions of the IL28B markers. The genotype distributions for the OASL rs10849829 polymorphisms (AA vs AG-GG) were significantly different between the CR and no-CR groups. In our series, for rs10849829, the OR of being a responder for the AA genotype compared to the AG and GG genotypes was 0.26 (95%CI: 0.07-0.88). CR was achieved in 5/21 (23.8%) of patients with the AA genotype at rs10849829, 14/25 (56.0%) patients with the genotype AG, and 3/6 (50.0%) patients with the genotype GG. Multivariate analysis for factors significantly associated with CR in univariate analysis showed only borderline significance for OASL rs10849829 AA ($P = 0.061$) in predicting a complete response.

**Impact of OAS and IL28B haplotypes on treatment responses**

Because all four OAS SNPs were located in a cluster on chromosome 12, we analysed the association of 4 SNPs with treatment response. First, we determined whether the four analysed SNPs were in strong linkage disequilibrium (LD). Overall, LD analysis demonstrated that rs1131476 OAS1, rs1293747 OAS2, rs2072136 OAS3 and rs10849829 OASL were in slight linkage disequilibrium (ranges, $D' = 0.358 - 0.999$, $r^2 = 0.023 - 0.382$). The strongest LD was noted for the OAS1 and OAS3 markers ($D' = 0.635$, $r^2 = 0.152$) and for the OAS2 and OAS3 markers ($D' = 0.999$, $r^2 = 0.382$). In the next step, we conducted a haplotype analysis of the 4 OAS SNPs. There were 6 common haplotypes with a frequency exceeding 5% in our study cohort (Table 4). The global tests revealed significant associations between OAS haplotype and PR and CR ($P = 0.0002$ and $P = 0.001$, respectively). Significant differences in haplotype frequencies between the CR and no-CR groups were noted for the G-A-G-G haplotype (28% vs 3%, $P = 0.0003$), the A-A-G-G haplotype (17% vs 34%, $P = 0.031$) and the G-G-G-G haplotype (5% vs 17%, $P = 0.046$). In addition, the haplotypes A-A-A-A and A-A-G-G were associated with the PR group rather than the no-PR group (16% vs 0%, $P = 0.041$ and 21% vs 57%, $P = 0.002$, respectively).

In our study cohort, the IL28B SNPs were in strong LD ($D' = 0.999$ for all pairs; $r^2$ ranges from 0.550 to 0.712). The global IL28B haplotype analyses indicated that the response groups (PR vs no-PR and CR vs no-CR) did not contain significantly different haplotype frequencies. However, the C-A-T haplotype (major alleles of all markers) was significantly associated with achieving CR (69% in the PR group vs 40% in the no-PR group, $P = 0.015$). In addition, for the T-G-G haplotype (minor alleles of all markers) there was a borderline significant difference between the CR and no-CR groups (16% vs 30%, $P = 0.09$) and the PR and no-PR groups (21% vs 40%, $P = 0.06$).

**DISCUSSION**

The limited efficacy, high cost and side effects associated with PEG-IFN treatment limit its clinical use in patients with CHB; however, this therapy is currently the only option for the permanent elimination of the virus [28]. Although viral clearance is rarely achieved with IFN treatment, it is more common with treatment than the natural rate of HBsAg seroclearance, which remains at a level of 2%-3% [29-31]. In this study of a group of paediatric patients, two (3.8%) patients permanently eliminated the virus.

Since there is no method of eradicating HBV, the current realistic goal of antiviral therapy is to achieve the permanent suppression of HBV replication to a level enabling the inhibition or retardation of inflammation and fibrosis of the liver and to protect against the development of hepatocellular carcinoma [28,32]. In the case of HBeAg-negative patients treated with IFN, reducing the viral load of HBV DNA after treatment to less than 2000 IU/mL is usually considered a

**Table 4 Association of OAS haplotypes with treatment response**

| Haplotype | CR | No-CR | $P$ value | OR (95%CI) | PR | No-PR | $P$ value | OR (95%CI) |
|-----------|----|-------|-----------|------------|----|-------|-----------|------------|
| A A A A   | 0.11 | 0.16  | 0.402     | 0.60 (0.18-1.98) | 0.16 | 0.00  | 0.041     | NA         |
| A A G A   | 0.03 | 0.05  | 0.473     | 0.47 (0.06-3.78) | 0.05 | 0.00  | 0.283     | NA         |
| A A G G   | 0.17 | 0.35  | 0.031     | 0.35 (0.13-0.92) | 0.21 | 0.57  | 0.002     | 0.21 (0.07-0.61) |
| A G G G   | 0.24 | 0.12  | 0.156     | 2.11 (0.74-6.00) | 0.17 | 0.13  | 0.543     | 1.55 (0.37-6.48) |
| G A G G   | 0.28 | 0.03  | 0.0003    | 11.96 (2.38-59.97) | 0.16 | 0.05  | 0.173     | 3.91 (0.48-31.8) |
| G G G G   | 0.05 | 0.17  | 0.046     | 0.24 (0.05-1.06) | 0.15 | 0.05  | 0.194     | 3.70 (0.45-30.25) |

Data are presented as the haplotype frequency; NA: Not applicable.
therapeutic success. The other endpoint of IFN therapy is a reduction in ALT to levels considered normal and the improvement of liver histology\(^{[28]}\). In our study, 42.3% of the patients achieved a complete response (HBV < 2000 IU/mL with ALT normalization), which is a result similar to the results obtained in other tests carried out among adult patients negative for HBe antigen\(^{[11,34,35]}\).

Identification of the molecular mechanisms affecting the efficacy of interferon therapies and the severity of side effects of the treatment remain one of the main objectives of the study. In the current study, we analysed the relationship between polymorphisms in the interleukin 28B gene and OAS gene family and the response to interferon therapy in children with CHB. In our previous study, which included adult patients, we demonstrated that IL28B markers are associated with response to interferon therapy in patients with HBeAg negative CHB\(^{[36]}\). Other previous studies tried to determine whether having a favourable IL28B genotype markers is associated with a better response to interferon therapy in HBeAg-negative adult patients, but the results were inconclusive. Some reports have suggested that the presence of favourable IL28B genotypes is associated with a better response to treatment\(^{[31,37]}\), while others have indicated that there is no association between IL28B SNPs and the response to treatment with interferon\(^{[18]}\).

In the present study, we demonstrated a statistically significant relationship between the rs12979860 marker and the response to treatment with interferon in patients with CHB. However, the results indicate the importance of the unfavourable TT genotype in estimating the chances of treatment failure.

Oligoadenylate synthetase plays a critical role in innate immunity, controlling the outcome of virus production. Consistent with the important role of OAS proteins in viral infection, it was shown that polymorphisms in the OAS genes are associated with increased susceptibility to HCV infection\(^{[18]}\) and IFN treatment outcomes\(^{[17,19,20]}\). However, the molecular basis for this association is not well understood. In several studies, it was shown that polymorphisms in the OAS genes result in variations in enzyme activity by influencing basal enzyme activity\(^{[39]}\), gene expression\(^{[17]}\) or cellular localization\(^{[40]}\).

In our study, we tried determine whether SNPs within the OAS genes may also affect the efficacy of interferon therapy in paediatric patients with CHB. In this study, a total of four SNPs located in the OAS1 (rs1131476), OAS2 (rs12937477), OAS3 (rs2072136) and OASL (rs10849829) genes were selected. The results of our study indicate that only the OASL rs10849829 marker has an impact on final therapeutic success, which was defined as the suppression of viral replication to an HBV DNA level < 2000 IU/mL and normalization of ALT activity 24 wk after completing treatment. The connection between the OAS gene polymorphisms and the efficacy of interferon therapy has not been extensively studied in patients with CHB. A small number of available studies have been carried out only in Han Chinese treatment-naïve CHB patients, who are representative of the Asian population\(^{[24,25]}\). The study of Wu et al\(^{[24]}\) demonstrated an association between interferon treatment and the haplotype G-T-G-A within the rs3177979G, rs12937477T, rs4767043G, and rs10849829A alleles, which occur in the OAS1, OAS2, OAS3, and OASL genes, respectively, instead of with OASL rs10849829. In this study, the authors suggested that patients with a G-T-G-A OAS haplotype were less responsive to IFN treatment. In agreement with the results of Wu et al\(^{[24]}\) we demonstrated that the AA genotype of rs10849829 was associated with failure of IFN therapy; however, there were no significant differences in allele frequencies between the different response groups. Additionally, the authors showed that the allele frequencies and genotype distributions of all the examined OAS SNPs were not correlated with treatment outcomes in patients who underwent IFN therapy. In another study conducted by Ren et al\(^{[25]}\), the influence of 4 SNPs - rs2285934 OAS1, rs2072138 OAS2, rs2072136 OAS3 and rs10849829 OASL - on the outcome of a 48-week IFN treatment of Han Chinese treatment-naïve CHB patients (265 HBeAg-positive, 55 HBeAg-negative, and 43 inactive HBsAg carriers) was evaluated. In this study, treatment response was defined as HBsAg seroconversion or HBeAg seroconversion for the patients who were HBeAg-positive, without HBsAg seroconversion. In contrast to our results, the allele frequencies and genotype distribution analysis of these SNPs showed that only the OAS3 SNP (rs2072136 T/C) was independently associated with IFN treatment response. However, OAS haplotype analysis demonstrated significant associations between haplotypes and response to IFN treatment. The most common haplotype C-C-T-A (rs2285934C, rs2072138C, rs2072136T and rs10849829A) was associated with non-response. Based on the results of these two studies, in our study we conducted a haplotype analysis of the 4 SNPs. Although the sample size was relatively small, we identified an association between the OAS haplotypes and PR and CR to IFN treatment.

In addition to the different endpoints of therapy, the reason for the discrepancies in the results of our work may be, as for other OAS gene polymorphisms, differences in the distribution of alleles between Caucasian and Asian populations. While the most common genotype for the rs10849829 marker is genotype AA (approx. 60%)\(^{[20]}\) in the Asian population, in our study, the percentage of patients with the AA genotype did not exceed 40%. The differences in the distribution of alleles between populations and their role in predicting response to interferon therapy in patients infected with HCV have been documented.
for IL28B polymorphisms\textsuperscript{[41]}. Additionally, Lampertico \textit{et al.}\textsuperscript{[42]} suggest that studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype. Although comparing the results for the Caucasian population with the results of the Asian population is difficult due to differences in the human alleles and HBV genotype distributions, it indicates the direction required for further studies, including those in Caucasian patients.

In summary, the presented study demonstrated a relationship between the IL28B rs12979860 and rs10849829 OASL genotypes, OAS haplotypes and the final IFN treatment outcome in paediatric patients infected with CHB. We noted that the unfavourable IL28B SNP genotype was present only in the no-CR group. Unlike adult studies, paediatric studies are definitely less frequent and are carried out in relatively small populations. Even the group we studied was not large enough to produce results that can be considered final. Nevertheless, this study indicates the potential markers we should focus on during further studies involving larger groups of patients.

**ACKNOWLEDGMENTS**

The authors thank Magdalena Wietlicka-Piszcz from the Department of Theoretical Foundations of Biomedical Sciences and Medical Computer Science, Collegium Medicum, Nicolaus Copernicus University, for reviewing the statistical analyses.

**REFERENCES**

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2833.2003.00487.x]
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500 [PMID: 18382247 DOI: 10.1056/NEJMra081644]
3. Crough CM, Luelb JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol 2014; 20: 10395-10404 [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395]
4. Abdel-Hady M, Kelly D. Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs 2013; 15: 311-317 [PMID: 23529864 DOI: 10.2472/0272-015-0030-z]
5. Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2015; 29: 907-917 [PMID: 26651252 DOI: 10.1016/j.bpg.2015.09.011]
6. Allison RD, Telb N, Al Awaidy S, Ashmony H, Alexander JP, Patet MK. Hepatitis B control among children in the Eastern Mediterranean Region of the World Health Organization. Vaccine 2016; 34: 2403-2409 [PMID: 27043863 DOI: 10.1016/j.vaccine.2016.03.063]
7. Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. J Infect Public Health 2016; 9: 389-395 [PMID: 26148849 DOI: 10.1016/j.jiph.2015.05.004]
8. Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011; 11: 285-300 [PMID: 21402745 DOI: 10.1517/14721298.2011.546340]
9. Rijckenborst V, Janssen HL. The Role of Interferon in Hepatitis B Therapy. Curr Hepat Rep 2010; 9: 231-238 [PMID: 20949114 DOI: 10.1007/s11901-010-0055-1]
10. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109 [PMID: 11438498 DOI: 10.1053/gast.2001.25524]
11. Marcellin P, Bonino F, Lau GK, Farci P, Yardyndin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.e1-4 [PMID: 19303414 DOI: 10.1053/j.gastro.2009.03.006]
12. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksey G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HeBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695 [PMID: 15987917 DOI: 10.1056/NEJMoa043470]
13. Bonjardim CA, Ferreira PC, Kroon EG. Interferons: signaling, antiviral and viral evasion. Immunol Lett 2009; 122: 1-11 [PMID: 19059436 DOI: 10.1016/j.imlet.2008.11.002]
of linkage disequilibrium, hepatocyte copy number, and genetic association at polymorphism loci. Cell Rep 2005; 15: 97-98 [PMID: 15740657 DOI: 10.1016/j.celrep.200727]
28 Sonneveld MJ, Jansen HL. Chronic hepatitis B. peginterferon or nucleos(t)ide analogues? Liver Int 2011; 31 Suppl 1: 78-84 [PMID: 21205142 DOI: 10.1111/j.1478-3231.2010.02384.x]
29 Liu J, Yang H, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 137: 474-482 [PMID: 20434450 DOI: 10.1053/j.gastro.2010.04.048]
30 Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133-143 [PMID: 20386608 DOI: 10.3851/IMP1497]
31 Lampertico P, Viganò M, Cheroni F, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abagnani S, De Francesco R, Colombo M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896 [PMID: 22473858 DOI: 10.1002/hep.25749]
32 Chen CJ, Yang H, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
33 Iloeje UH, Yang H, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2010; 136: 678-686 [PMID: 16535009 DOI: 10.1053/j.gastro.2005.11.016]
34 Marcellin P, Lai GK, Bonino F, Facciponti D, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germainidis G, Yurdaydin C, Di Maio G, Garel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217 [PMID: 15371578 DOI: 10.1056/NEJMoa040431]
35 Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Jansen HL. A randomized trial of peginterferon alfa-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762-1769 [PMID: 20461068 DOI: 10.1111/j.1572-0241.2010.03421.x]
36 Domagalski K, Pawlovska M, Zaleina A, Tyczyno M, Skorupa-Klaput M, Tretyn A, Halota W. The relationship between IL-28B polymorphisms and response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. Eur J Clin Microbiol Infect Dis 2013; 33: 2025-2033 [PMID: 24924923 DOI: 10.1007/s10096-014-2172-1]
37 Boglole L, Cusato J, Allegra S, Esposito I, Patti F, Cariti G, Di Perri G, D’Avolio A. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res 2014; 102: 35-43 [PMID: 24316030 DOI: 10.1016/j.antiviral.2013.11.004]
38 Brouwer WP, Arends P, Rikhorst V. Polymorphisms near the IL28B gene are not associated with response to peginterferon in HBeAg-negative chronic hepatitis B patients. J Hepatol 2013; 58: S299 [DOI: 10.1016/S0168-8278(13)60739-4]
39 Bonnevie-Nielsen V, Field LL, Lu S, Zheng DJ, Li M, Martensen PM, Nielsen TB, Beck-Nielsen H, Lau YL, Pocic F. Variation in antiviral 2',5'-oligoadenylate synthetase (2’5’AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005; 76: 623-633 [PMID: 15732009 DOI: 10.1086/429391]
40 Kjær KH, Palhus J, Hansen MF, Poulsen JB, Christensen EI, Justesen J, Madsen PM. Mitochondrial localization of the OAS1 p46 isoform associated with a common single nucleotide polymorphism. BMC Cell Biol 2014; 15: 33 [PMID: 25205466 DOI: 10.1186/1471-2121-15-33]
McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]

42 Lampertico P, Galmozzi E, Colombo M. [Not Available]. *Hepatology* 2013; 57: 1283-1284 [PMID: 22707216 DOI: 10.1002/hep.25882]

P- Reviewer: Higuera-de la Tijera MF   S- Editor: Qi Y   L- Editor: A   E- Editor: Wang CH
